AgingResearch.NewsJoin free

Elysium Health

CompanyUnited StatesFounded 2014

RORWikidata

Elysium Health develops 14 assets, the furthest in phase 3 (creatine in amyotrophic lateral sclerosis). Mostly supplement and other acting on sirtuin signalling, NAD+ metabolism and oxidative phosphorylation; based in the United States, founded in 2014.

14
Assets
Furthest
Phase 3
Raised
US$60m
1
Grant
1
Trial
0
Signals

Pipeline

14

  • creatine

    Replenishes cellular phosphocreatine pools to maintain mitochondrial energy production and ATP homeostasis.

    Phase 3, Supplement, Oxidative phosphorylation, CKMT1A, amyotrophic lateral sclerosis

  • Basis

    Increases NAD+ levels.

    Phase 2, Supplement, acute kidney injury, cellular aging (Human trials)

  • Niagen

    Nicotinamide riboside acts as an NAD+ precursor to increase NAD+ levels.

    Phase 1, Supplement, Sirtuin signalling, NAD+ metabolism, fatigue, pharmacokinetic

11 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms7
  • Trials7
  • Funding rounds and grants2
  • People24
  • Signals1
  • Similar companies6

Updated 11 Oct 2026 · 47 sources

Intelligence